EGFR and colorectal cancer: In a large cohort of colorectal cancer patients, ctDNA analysis allowed the identification of actionable gene fusions, including 10 ALK fusion-positive patients; 7/10 samples also carried additional mutations in EGFR, KRAS and NRAS genes and were associated with resistance to anti-EGFR therapy [173].